Jonathan Carapetis AM JR AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@ ...

• Telethon Kids Institute
• Projects

Children with Down syndrome (DS) are at a significantly higher risk of developing acute myeloid leukemia, also termed myeloid leukemia associated with DS (ML-DS). In contrast to the highly favorable prognosis of primary ML-DS, the limited data that are available for children who relapse or who have refractory ML-DS (r/r ML-DS) suggest a dismal prognosis. There are few clinical trials and no standardized treatment approach for this population. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• February 2023

Aboriginal children living in remote communities are at high risk of early and persistent otitis media. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are primary pathogens. Vaccines with potential to prevent early OM have not been evaluated in this population. We compared immunogenicity (ELISA and opsonophagocytic activity) of a combination of Synflorix™ (PHiD-CV10, 10 serotypes and protein D of NTHi) and Prevenar13™ (PCV13, 10 serotypes plus 3, 6A, and 19A), with recommended schedules. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2021
• February 2021

KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2023
• April 2023

Acute lymphoblastic leukemia (ALL) in infants younger than 1 year of age is an aggressive, high-risk subtype of childhood ALL. Infant ALL with KMT2A-r is characteristically poorly responsive to chemotherapy and hematopoietic stem cell transplantation. New strategies, such as molecularly targeted therapies and immunotherapies, are in development and show promise in preclinical models and early phase studies. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2022
• January 2022

Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortality and a major contributor to disability. This paper reviews the magnitude of total CVD burden, including 13 underlying causes of cardiovascular death and 9 related risk factors, using estimates from the Global Burden of Disease (GBD) Study 2019. GBD, an ongoing multinational collaboration to provide comparable and consistent estimates of population health over time, used all available population-level data sources on incidence, prevalence, case fatality, mortality, and health risks to produce estimates for 204 countries and territories from 1990 to 2019. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2020
• December 2020

Australia’s first comprehensive research centre focused on mental health from birth to 25 years has been launched today in Perth. ...

• Telethon Kids Institute
• News & Events
• News & Events at Telethon Kids
• 2019
• May

Hundreds of researchers from Perth's Telethon Institute for Child Health Research will join a rally in Forrest Place today ...

• Telethon Kids Institute
• News & Events
• News & Events at Telethon Kids
• 2011
• April

Chris Peter Brennan-Jones Richmond C PC PhD MBBS MRCP(UK) FRACP Head, Ear Health Head, Vaccine Trials Group chris.brennan-jones@telethonkids.org.au ...

• Telethon Kids Institute
• Projects

Prevalence of skin sores and scabies in remote Australian Aboriginal communities remains unacceptably high, with Group A Streptococcus (GAS) the dominant pathogen. We aim to better understand the drivers of GAS transmission using mathematical models. ...

• Telethon Kids Institute
• Our research
• Reports and Findings
• 2018
• May 2018